Acknowledgments
This work was funded and supported by FAPESP (Sa ˜o Paulo
Research Foundation, grants 2014/10068-4, 2017/25588-1,
2016/07948-8, 2018/03422-7, 2019/00098-7, and 2019/
05747-3) and CNPq (Conselho Nacional de Desenvolvimento
Cientı ´fico e Tecnolo ´ gico, grants 135680/2016-6, 144417/
2017-0, and 302453/2017-2).
References
1. Campbell DD, Li Y, Sham PC (2018) Multifactorial disease risk calculator: risk prediction
for multifactorial disease pedigrees. Genet Epidemiol 42:130–133. https://doi.org/10.
1002/gepi.22101
2. Guest FL, Guest PC, Martins-de-Souza D
(2016) The emergence of point-of-care
blood-based biomarker testing for psychiatric
disorders: enabling personalized medicine.
Biomark Med 10:431–443. https://doi.org/
10.2217/bmm-2015-0055
3. Guest PC, Martins-de-Souza D (2017)
Enabling point-of-care testing and personalized medicine for schizophrenia. NPJ Schizophr
3:1.
https://doi.org/10.1038/
s41537-016-0005-1
4. Patel S (2014) Role of proteomics in biomarker
discovery: prognosis and diagnosis of neuropsychiatric disorders. Adv Protein Chem Struct
Biol 94:39–75. https://doi.org/10.1016/
B978-0-12-800168-4.00003-2
5. Wu CC, MacCoss MJ (2002) Shotgun proteomics: tools for the analysis of complex
biological systems. Curr Opin Mol Ther
4:242–250
6. Aebersold R, Mann M (2016) Massspectrometric exploration of proteome structure and function. Nature 537:347–355.
https://doi.org/10.1038/nature19949
7. Jain KK (2016) Role of proteomics in the
development of personalized medicine. Adv
Protein Chem Struct Biol 102:41–52
8. Tirumalai RS, Chan KC, Prieto DA et al
(2003) Characterization of the low molecular
weight human serum proteome. Mol Cell Proteomics 2:1096–1103. https://doi.org/10.
1074/mcp.M300031-MCP200
9. Pieper R, Gatlin CL, Makusky AJ et al (2003)
The human serum proteome: display of nearly
3700 chromatographically separated protein
spots on two-dimensional electrophoresis gels
and identification of 325 distinct proteins. Proteomics 3:1345–1364. https://doi.org/10.
1002/pmic.200300449
10. Anderson NL, Anderson NG (2002) The
human plasma proteome: history, character,
and diagnostic prospects. Mol Cell Proteomics
1:845–867. https://doi.org/10.1074/mcp.
r200007-mcp200
11. Schwenk JM, Omenn GS, Sun Z et al (2017)
The human plasma proteome draft of 2017:
building on the human plasma PeptideAtlas
from mass spectrometry and complementary
assays. J Proteome Res 16:4299–4310.
https://doi.org/10.1021/acs.jproteome.
7b00467
12. Gianazza E, Miller I, Palazzolo L et al (2016)
With or without you - proteomics with or
without major plasma/serum proteins. J Proteome 140:62–80. https://doi.org/10.1016/
j.jprot.2016.04.002
13. Smith MPW, Wood SL, Zougman A et al
(2011) A systematic analysis of the effects of
increasing degrees of serum immunodepletion
in terms of depth of coverage and other key
aspects in top-down and bottom-up proteomic
analyses. Proteomics 11:2222–2235. https://
doi.org/10.1002/pmic.201100005
14. Roche S, Tiers L, Provansal M et al (2009)
Depletion of one, six, twelve or twenty major
blood proteins before proteomic analysis: the
more the better? J Proteome 72:945–951.
https://doi.org/10.1016/j.jprot.2009.03.
008
15. Jaros JAJ, Guest PC, Bahn S, Martins-deSouza D (2013) Affinity depletion of plasma
and serum for mass spectrometry-based proteome analysis. Methods Mol Biol 1002:1–11.
https://doi.org/10.1007/978-1-62703-3602_1
16. Tu C, Rudnick PA, Martinez MY et al (2010)
Depletion of abundant plasma proteins and
limitations of plasma proteomics. J Proteome
Res 9:4982–4991. https://doi.org/10.1021/
pr100646w
17. Garcia S, Silva-Costa LC, Reis-de-Oliveira G
et al (2017) Identifying biomarker candidates
164
Licia C. Silva-Costa et al.
This work was funded and supported by FAPESP (Sa ˜o Paulo
Research Foundation, grants 2014/10068-4, 2017/25588-1,
2016/07948-8, 2018/03422-7, 2019/00098-7, and 2019/
05747-3) and CNPq (Conselho Nacional de Desenvolvimento
Cientı ´fico e Tecnolo ´ gico, grants 135680/2016-6, 144417/
2017-0, and 302453/2017-2).
References
1. Campbell DD, Li Y, Sham PC (2018) Multifactorial disease risk calculator: risk prediction
for multifactorial disease pedigrees. Genet Epidemiol 42:130–133. https://doi.org/10.
1002/gepi.22101
2. Guest FL, Guest PC, Martins-de-Souza D
(2016) The emergence of point-of-care
blood-based biomarker testing for psychiatric
disorders: enabling personalized medicine.
Biomark Med 10:431–443. https://doi.org/
10.2217/bmm-2015-0055
3. Guest PC, Martins-de-Souza D (2017)
Enabling point-of-care testing and personalized medicine for schizophrenia. NPJ Schizophr
3:1.
https://doi.org/10.1038/
s41537-016-0005-1
4. Patel S (2014) Role of proteomics in biomarker
discovery: prognosis and diagnosis of neuropsychiatric disorders. Adv Protein Chem Struct
Biol 94:39–75. https://doi.org/10.1016/
B978-0-12-800168-4.00003-2
5. Wu CC, MacCoss MJ (2002) Shotgun proteomics: tools for the analysis of complex
biological systems. Curr Opin Mol Ther
4:242–250
6. Aebersold R, Mann M (2016) Massspectrometric exploration of proteome structure and function. Nature 537:347–355.
https://doi.org/10.1038/nature19949
7. Jain KK (2016) Role of proteomics in the
development of personalized medicine. Adv
Protein Chem Struct Biol 102:41–52
8. Tirumalai RS, Chan KC, Prieto DA et al
(2003) Characterization of the low molecular
weight human serum proteome. Mol Cell Proteomics 2:1096–1103. https://doi.org/10.
1074/mcp.M300031-MCP200
9. Pieper R, Gatlin CL, Makusky AJ et al (2003)
The human serum proteome: display of nearly
3700 chromatographically separated protein
spots on two-dimensional electrophoresis gels
and identification of 325 distinct proteins. Proteomics 3:1345–1364. https://doi.org/10.
1002/pmic.200300449
10. Anderson NL, Anderson NG (2002) The
human plasma proteome: history, character,
and diagnostic prospects. Mol Cell Proteomics
1:845–867. https://doi.org/10.1074/mcp.
r200007-mcp200
11. Schwenk JM, Omenn GS, Sun Z et al (2017)
The human plasma proteome draft of 2017:
building on the human plasma PeptideAtlas
from mass spectrometry and complementary
assays. J Proteome Res 16:4299–4310.
https://doi.org/10.1021/acs.jproteome.
7b00467
12. Gianazza E, Miller I, Palazzolo L et al (2016)
With or without you - proteomics with or
without major plasma/serum proteins. J Proteome 140:62–80. https://doi.org/10.1016/
j.jprot.2016.04.002
13. Smith MPW, Wood SL, Zougman A et al
(2011) A systematic analysis of the effects of
increasing degrees of serum immunodepletion
in terms of depth of coverage and other key
aspects in top-down and bottom-up proteomic
analyses. Proteomics 11:2222–2235. https://
doi.org/10.1002/pmic.201100005
14. Roche S, Tiers L, Provansal M et al (2009)
Depletion of one, six, twelve or twenty major
blood proteins before proteomic analysis: the
more the better? J Proteome 72:945–951.
https://doi.org/10.1016/j.jprot.2009.03.
008
15. Jaros JAJ, Guest PC, Bahn S, Martins-deSouza D (2013) Affinity depletion of plasma
and serum for mass spectrometry-based proteome analysis. Methods Mol Biol 1002:1–11.
https://doi.org/10.1007/978-1-62703-3602_1
16. Tu C, Rudnick PA, Martinez MY et al (2010)
Depletion of abundant plasma proteins and
limitations of plasma proteomics. J Proteome
Res 9:4982–4991. https://doi.org/10.1021/
pr100646w
17. Garcia S, Silva-Costa LC, Reis-de-Oliveira G
et al (2017) Identifying biomarker candidates
164
Licia C. Silva-Costa et al.